Treatment of Hepatitis C Virus Infection in Children Less than 12 Years of Age in Developing Countries

The treatment of hepatitis c virus (HCV) infection in children is difficult as few options are available. The standard therapy is combination pegylated interferon (PEG–IFN) α-2a or 2b and ribavirin, and the duration of therapy depends on HCV genotype. New oral drug therapies available for adults hav...

Descripción completa

Detalles Bibliográficos
Autor principal: Aziz, Sina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: XIA & HE Publishing Ltd 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521235/
https://www.ncbi.nlm.nih.gov/pubmed/26356647
http://dx.doi.org/10.14218/JCTH.2014.00034
_version_ 1782383776982106112
author Aziz, Sina
author_facet Aziz, Sina
author_sort Aziz, Sina
collection PubMed
description The treatment of hepatitis c virus (HCV) infection in children is difficult as few options are available. The standard therapy is combination pegylated interferon (PEG–IFN) α-2a or 2b and ribavirin, and the duration of therapy depends on HCV genotype. New oral drug therapies available for adults have still not been approved for treatment in children. Here, we review the causes of HCV infection in children, the therapeutic options for children, and the side effects of these treatments. The problems faced by physicians managing HCV infection in children less than 12 years of age in a developing country are also discussed.
format Online
Article
Text
id pubmed-4521235
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher XIA & HE Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-45212352015-09-09 Treatment of Hepatitis C Virus Infection in Children Less than 12 Years of Age in Developing Countries Aziz, Sina J Clin Transl Hepatol Review Article The treatment of hepatitis c virus (HCV) infection in children is difficult as few options are available. The standard therapy is combination pegylated interferon (PEG–IFN) α-2a or 2b and ribavirin, and the duration of therapy depends on HCV genotype. New oral drug therapies available for adults have still not been approved for treatment in children. Here, we review the causes of HCV infection in children, the therapeutic options for children, and the side effects of these treatments. The problems faced by physicians managing HCV infection in children less than 12 years of age in a developing country are also discussed. XIA & HE Publishing Ltd 2014-12-15 2014-12 /pmc/articles/PMC4521235/ /pubmed/26356647 http://dx.doi.org/10.14218/JCTH.2014.00034 Text en © 2014 The Second Affiliated Hospital of Chongqing Medical University. Published by XIA & HE Publishing Ltd. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Aziz, Sina
Treatment of Hepatitis C Virus Infection in Children Less than 12 Years of Age in Developing Countries
title Treatment of Hepatitis C Virus Infection in Children Less than 12 Years of Age in Developing Countries
title_full Treatment of Hepatitis C Virus Infection in Children Less than 12 Years of Age in Developing Countries
title_fullStr Treatment of Hepatitis C Virus Infection in Children Less than 12 Years of Age in Developing Countries
title_full_unstemmed Treatment of Hepatitis C Virus Infection in Children Less than 12 Years of Age in Developing Countries
title_short Treatment of Hepatitis C Virus Infection in Children Less than 12 Years of Age in Developing Countries
title_sort treatment of hepatitis c virus infection in children less than 12 years of age in developing countries
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521235/
https://www.ncbi.nlm.nih.gov/pubmed/26356647
http://dx.doi.org/10.14218/JCTH.2014.00034
work_keys_str_mv AT azizsina treatmentofhepatitiscvirusinfectioninchildrenlessthan12yearsofageindevelopingcountries

Ejemplares similares